A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

147 sites for NCT04293562

BCR-ABL1 Fusion, +48 more biomarkers

Acute Myeloid Leukemia

allogeneic hematopoietic stem cell transplantation, +12 more drugs

cellular therapy, +4 more types

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

78 sites for NCT02693535

AKT1 Mutation, +128 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +19 more conditions

abemaciclib, +23 more drugs

immunotherapy, +1 more type

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

33 sites for NCT04971226

BCR-ABL1 Fusion, +1 more biomarker

Chronic Myeloid Leukemia

asciminib

targeted therapy

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

105 sites for NCT04530565

ABL1 T315I, +2 more biomarkers

B-Cell Acute Lymphoblastic Leukemia

allogeneic hematopoietic stem cell transplantation, +10 more drugs

cellular therapy, +4 more types

A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

198 sites for NCT04102020

BCR-ABL1 Fusion, +47 more biomarkers

Acute Myeloid Leukemia

azacitidine, +1 more drug

chemotherapy

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

178 sites for NCT03007147

BCR-ABL1 Fusion, +1 more biomarker

Acute Lymphoblastic Leukemia

allogeneic hematopoietic stem cell transplantation, +18 more drugs

cellular therapy, +4 more types

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

109 sites for NCT03589326

BCR-ABL1 Fusion, +1 more biomarker

Acute Lymphoblastic Leukemia

cytarabine, +5 more drugs

chemotherapy, +2 more types

Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

48 sites for NCT02416388

BCR-ABL1 Fusion, +24 more biomarkers

Acute Myeloid Leukemia

cyclosporine, +5 more drugs

chemotherapy, +1 more type

Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE

42 sites for NCT01491763

BCR-ABL1 Fusion, +1 more biomarker

Acute Lymphoblastic Leukemia

cytarabine, +8 more drugs

chemotherapy, +2 more types

Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)

14 sites for NCT04571645

ASXL1 Loss, +27 more biomarkers

Acute Myeloid Leukemia

chemotherapy, +1 more drug

chemotherapy, +1 more type

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

175 sites for NCT03516279

BCR-ABL1 Fusion, +1 more biomarker

Chronic Myeloid Leukemia

dasatinib, +3 more drugs

immunotherapy, +1 more type

Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

1 site for NCT04845035

BCR-ABL1 Fusion, +1 more biomarker

Acute Lymphoblastic Leukemia

BFM regimen, +4 more drugs

chemotherapy, +1 more type